Propionate, a short-chain fatty acid, is associated with disease activity in pediatric-onset multiple sclerosis.

Propionate levels in plasma and paired stool samples are consistently linked to lower disease activity in pediatric-onset multiple sclerosis, with replication in an external cohort.

• Why it matters: The study addresses whether gut-derived short-chain fatty acids relate to early MS activity, filling a gap in understanding gut-brain metabolic markers at disease onset.
• What they did: In a large, deeply phenotyped cohort shortly after MS onset, targeted mass spectrometry measured SCFAs in plasma and paired stool samples, and propionate associations were tested again in an equally large external cohort.
• The result: Propionate shows consistent protective associations across three clinical and imaging activity-related outcomes, while it is not correlated with dietary fiber and may support exogenous administration over fiber supplementation in proof-of-concept trials.

AI summary of the abstract · may contain errors · not medical advice · read the paper.